Equities Analysts Issue Forecasts for CervoMed FY2025 Earnings

CervoMed Inc. (NASDAQ:CRVO) – Research analysts at Brookline Capital Acquisition issued their FY2025 earnings estimates for shares of CervoMed in a note issued to investors on Tuesday, February 3rd. Brookline Capital Acquisition analyst F. Ahmed anticipates that the company will post earnings of ($2.65) per share for the year. Brookline Capital Acquisition currently has a “Strong-Buy” rating on the stock. The consensus estimate for CervoMed’s current full-year earnings is ($1.88) per share. Brookline Capital Acquisition also issued estimates for CervoMed’s Q4 2025 earnings at ($0.78) EPS.

CervoMed (NASDAQ:CRVO) last released its quarterly earnings data on Friday, November 7th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.16). CervoMed had a negative return on equity of 76.78% and a negative net margin of 415.27%.The business had revenue of $0.32 million for the quarter, compared to analyst estimates of $1.43 million.

CRVO has been the subject of several other research reports. Brookline Cap M upgraded shares of CervoMed to a “strong-buy” rating in a research report on Tuesday. D. Boral Capital reissued a “buy” rating and issued a $31.00 price target on shares of CervoMed in a research report on Tuesday, December 2nd. Zacks Research upgraded shares of CervoMed from a “strong sell” rating to a “hold” rating in a research note on Monday, January 12th. Roth Mkm set a $20.00 price objective on CervoMed and gave the stock a “buy” rating in a report on Friday, October 17th. Finally, Cantor Fitzgerald started coverage on CervoMed in a report on Thursday, December 18th. They issued an “overweight” rating for the company. Two research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, CervoMed has an average rating of “Moderate Buy” and an average price target of $22.17.

CervoMed Stock Up 15.4%

Shares of CRVO opened at $5.31 on Friday. The company has a market capitalization of $49.12 million, a price-to-earnings ratio of -1.83 and a beta of -0.82. CervoMed has a 52-week low of $1.92 and a 52-week high of $16.94. The stock has a 50 day moving average price of $7.36 and a 200 day moving average price of $8.14.

Insider Activity at CervoMed

In other news, CEO John J. Alam bought 10,793 shares of the firm’s stock in a transaction on Monday, November 17th. The shares were bought at an average cost of $8.46 per share, for a total transaction of $91,308.78. Following the completion of the transaction, the chief executive officer owned 12,500 shares in the company, valued at $105,750. This trade represents a 632.28% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Sylvie Gregoire bought 10,807 shares of the stock in a transaction on Monday, November 17th. The stock was purchased at an average cost of $8.46 per share, for a total transaction of $91,427.22. Following the acquisition, the director directly owned 12,500 shares of the company’s stock, valued at $105,750. The trade was a 638.33% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased 92,000 shares of company stock worth $737,723 over the last 90 days. Company insiders own 35.40% of the company’s stock.

Institutional Investors Weigh In On CervoMed

Several institutional investors and hedge funds have recently made changes to their positions in the business. Citizens Financial Group Inc. RI raised its stake in CervoMed by 23.0% during the fourth quarter. Citizens Financial Group Inc. RI now owns 37,477 shares of the company’s stock worth $296,000 after purchasing an additional 7,000 shares during the period. Byrne Asset Management LLC acquired a new stake in shares of CervoMed during the 4th quarter worth $116,000. Citadel Advisors LLC purchased a new position in shares of CervoMed in the 3rd quarter worth $247,000. Two Sigma Investments LP purchased a new position in shares of CervoMed in the 3rd quarter worth $138,000. Finally, Readystate Asset Management LP acquired a new position in CervoMed in the third quarter valued at $118,000. 25.15% of the stock is currently owned by hedge funds and other institutional investors.

CervoMed Company Profile

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc was founded in 2010 and is headquartered in Boston, Massachusetts.